Barrington Research Maintains Outperform on Haemonetics, Raises Price Target to $140
Barrington Research analyst Michael Petusky maintains Haemonetics (NYSE:HAE) with a Outperform and raises the price target from $118 to $140.
Stocks · News reference
Haemonetics Q1 2027 Earnings Call Transcript
Haemonetics (NYSE:HAE) released first-quarter financial results and hosted an earnings call on Thursday. Read the complete transcript below. This transcript is brought to you by Benzinga APIs. For real-time access to
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Mizuho Maintains Outperform on Haemonetics, Raises Price Target to $140
Mizuho analyst Anthony Petrone maintains Haemonetics (NYSE:HAE) with a Outperform and raises the price target from $95 to $140.
Haemonetics shares are trading higher after BTIG maintained its Buy rating on the stock and raised its price target from $110 to $130.
BTIG Maintains Buy on Haemonetics, Raises Price Target to $130